Updates Center

• 
  International Life Sciences Leaders Visit AtaGenix: Advancing Antibody R&D with Velocity and Rigor

  On October 14, 2025, AtaGenix in Wuhan, China, welcomed global life sciences representatives to explore its 6-month antibody R&D platform, marking a biotech collaboration milestone.
• 
  COMPANY ANNOUNCEMENT

  AtaGenix Laboratories Co., Ltd. issues a formal statement addressing the unauthorized use of its name by Wuhan Biolab-reagent, which forged documents and official seals, constituting illegal activity and unfair competition. The company clarifies that no business agreements exist with Wuhan Biolab-reagent, condemns their actions, and reserves the right to pursue legal action under Chinese intellectual property and criminal laws. AtaGenix advises partners to verify document authenticity to avoid legal and financial risks, reaffirming its commitment to honest operation and industry fairness.
• 
  AI-Powered Antibody Discovery: AtaGenix Leverages Cutting-Edge Technology to Slash Development Timelines

  On October 14, 2025, the biopharmaceutical industry is being reshaped by AI-driven antibody design, slashing development timelines from months to weeks with up to 100-fold efficiency gains. AtaGenix Laboratories leverages DeepMind’s AlphaFold to tackle complex CDR regions, generating high-affinity antibodies (Kd < 1 nM) for targets like GPCR and PD-L1. By integrating AI with robust wet-lab validation, including phage display and single B-cell cloning, AtaGenix mitigates data scarcity issues and reduces costs to <5% of traditional methods. Emerging tools like Chai-2 further highlight the field’s potential, achieving zero-shot de novo design with 16-20% hit rates. AtaGenix’s approach empowers clients to shift focus from discovery to clinical execution, redefining drug discovery economics.
• 
  Antibody Discovery Paradigm Shift: Single B-Cell Cloning Challenges Phage Display Dominance

  On September 29, 2025, the antibody development field sees a pivotal shift as single B-cell cloning gains momentum, challenging the dominance of phage display. Known for its vast libraries, phage display is being rivaled by B-cell cloning’s ability to capture high-affinity, natural antibodies with low immunogenicity. AtaGenix leverages both platforms, offering services like antibody development, recombinant protein expression, and humanization to accelerate client projects, reducing discovery timelines by over 30%.
• 
  AtaGenix September 2025 Literature Collection: Advancing Life Sciences Through Cutting-Edge Research Support

  The AtaGenix September 2025 Literature Collection highlights the company’s pivotal role in supporting groundbreaking life science research. Featuring studies published in high-impact journals like Journal of Nanobiotechnology and Cell Reports, this collection showcases advancements in lipid nanoparticle-based mRNA vaccines, gastric cancer drug resistance mechanisms, LayV virus antigenicity, jujube centromere evolution, and tomato plant vigor regulation. AtaGenix’s technical services, including custom antibodies and hybridoma screening tools, were instrumental in these discoveries, reinforcing its commitment to driving innovation in life sciences.
• 
  AtaGenix Excels at Thailand LAB International 2025: Pioneering Antibody Discovery & Protein Expression

  AtaGenix Laboratories Co., Ltd. participated in Thailand LAB International 2025 in Bangkok from September 3-5, showcasing advanced antibody discovery and protein expression technologies at booth 2S21. Through technical exhibits, seminars, and business discussions, AtaGenix established global partnerships, reinforcing its leadership in the Asia-Pacific biotechnology market.
• 
  Analysis Forecasts First Commercial Bispecific ADC Launch by 2029 Amid Surging Clinical Pipeline

  A recent industry analysis forecasts the first commercial launch of a bispecific antibody–drug conjugate (BsADC) by 2029, marking a major milestone in multispecific biologics. With 100+ BsADC candidates in clinical development, including more than 60 from China, the field is expanding rapidly. Advances in linker–payload technologies, bispecific formats, and regulatory learning from earlier ADCs are accelerating progress. For developers, this trend highlights both opportunity and competition. AtaGenix supports BsADC innovation with expertise in bispecific design, conjugation strategies, and early-stage engineering—helping partners gain a competitive edge in next-generation oncology therapeutics.
• 
  Global Antibody Discovery Market to Soar from USD 1.9B in 2024 to USD 3.3B by 2030

  The global antibody discovery market, valued at USD 1.9 billion in 2024, is projected to reach USD 3.3 billion by 2030, with a CAGR of 9.8%. Growth is fueled by expanding pipelines in monoclonal antibodies, rapid adoption of bispecifics, and increasing investment in antibody–drug conjugates (ADCs). Advances in single B-cell technologies, AI-driven design, and stable cell line development are accelerating discovery and reducing development risks. As demand rises for next-generation biologics, AtaGenix provides integrated discovery, screening, and engineering platforms to help researchers and partners achieve faster, cost-effective progress.
• 
  VINS Visits AtaGenix Wuhan HQ for Biopharma Partnership

  On June 25, 2025, VINS Bioproducts visited AtaGenix’s Wuhan headquarters to expand collaboration on vaccine raw materials, antibody R&D, and CRO services—advancing public health and innovation.
• 
  BioTAG Visits AtaGenix Headquarters to Advance Antibody Drug Development and Precision Medicine

  On August 13, 2025, BioTAG from Israel visited AtaGenix’s Wuhan headquarters to discuss antibody drug development, protein engineering, and CRO services. The collaboration aims to advance precision medicine and biopharmaceutical innovation globally.